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TP53 mutations confer subgroup specific poor survival for children with medulloblastoma. We hypothesized that WNT
activation which is associated with improved survival for such children abrogates TP53 related radioresistance and can
be used to sensitize TP53 mutant tumors for radiation. We examined the subgroup-specific role of TP53 mutations in a
cohort of 314 patients treated with radiation. TP53 wild-type or mutant human medulloblastoma cell-lines and normal
neural stem cells were used to test radioresistance of TP53 mutations and the radiosensitizing effect of WNT activation
on tumors and the developing brain. Children with WNT/TP53 mutant medulloblastoma had higher 5-year survival than
those with SHH/TP53 mutant tumours (100% and 36.6% ± 8.7%, respectively (p < 0.001)). Introduction of TP53 mutation
into medulloblastoma cells induced radioresistance (survival fractions at 2Gy (SF2) of 89% ± 2% vs. 57.4% ± 1.8%
(p < 0.01)). In contrast, β-catenin mutation sensitized TP53 mutant cells to radiation (p < 0.05). Lithium, an activator
of the WNT pathway, sensitized TP53 mutant medulloblastoma to radiation (SF2 of 43.5% ± 1.5% in lithium treated
cells vs. 56.6 ± 3% (p < 0.01)) accompanied by increased number of γH2AX foci. Normal neural stem cells were
protected from lithium induced radiation damage (SF2 of 33% ± 8% for lithium treated cells vs. 27% ± 3% for untreated
controls (p = 0.05). Poor survival of patients with TP53 mutant medulloblastoma may be related to radiation resistance.
Since constitutive activation of the WNT pathway by lithium sensitizes TP53 mutant medulloblastoma cells and protect
normal neural stem cells from radiation, this oral drug may represent an attractive novel therapy for high-risk
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Medulloblastoma is the most common malignant brain
tumor of childhood [1]. Survival of these children has
improved in the last two decades due to collaborative
studies utilizing aggressive surgical resection, high dose
craniospinal irradiation and chemotherapy [2-4]. This
aggressive approach to therapy has come at a severe cost
with the majority patients suffering significant long-term
neurocognitive, endocrine and other toxicities [5]. Re-
cent progress in the molecular stratification of medullo-
blastoma has revealed striking heterogeneity that has led
to stratification into several genetically distinct clinical
subgroups (WNT, SHH, Group 3, Group 4) which re-
spond differently to current therapies [6].
Of the four subgroups, patients with WNT subgroup
medulloblastoma exhibit an excellent overall survival
(OS), those with SHH medulloblastoma have an inter-
mediate long-term survival, whereas those with Groups
3 and 4 disease have particularly decimal outcomes [7,8].
Recent studies highlighted the role of additional genetic
alterations in identifying risk factors in each molecular
subgroup. For example, iso17q together with MYC amp-
lification define the high risk patients in group 3, but
not group 4. In contrast, Group 4 patients with whole
chromosome 11 loss, or chromosome 17 gain together
with loss of chromosome 10p, demonstrate better survival.
Absence of GLI2 amplification and 14q loss identify a
low-risk patient population, chromothripsis is found in
SHH patients with inferior outcomes, and monosomy of
chromosome 6 carries favorable prognostic value only
within the WNT subgroup [9].
Our group has recently uncovered the role of TP53
mutations in clinically distinct subgroups of medullo-
blastoma [10]. TP53 mutations are restricted to the SHH
and WNT subgroups. In the former it is associated with
poor survival while in the latter, this survival disadvan-
tage is not seen [10].
TP53 is mutated or deleted in over 50% of human can-
cers resulting in loss of p53-associated apoptosis, cell
cycle arrest or DNA brake/repair response [11]; Loss of
normal p53 function and resultant impaired G1 check
point control correlates with increased resistance to both
low- and high-dose ionizing radiation in several cancers
including medulloblastoma [12-21]. It is argued that,
though tissue specific, TP53 mutation status can predict
tumor radiosensitivity and a patient’s response to radi-
ation therapy [19,20].
Craniospinal radiation therapy remains the corner-
stone of treatment in childhood medulloblastoma. It is,
therefore, reasonable to hypothesize that the poor sur-
vival of patients with TP53 mutant medulloblastoma is
related to radioresistance of these cancers. In contrast,
in 10-15% of medulloblastoma displaying activation of
the WNT/β-catenin pathway TP53 mutant status doesnot negatively influence survival [18,22,23]. In the WNT
subgroup, patients with either wild-type or mutant TP53
tumors respond equally well to radiotherapy. Most
WNT subgroup tumors harbor activating mutations in
exon 3 of the β-catenin gene, and this genetic alteration
is a universally favorable prognostic marker for both
average- and high-risk patients, and long term patient
survival exceeds 90% [3,6,7,22,24-28].
Lithium is a non-competitive and specific inhibitor of
GSK3β which is a negative regulator of the WNT path-
way. Lithium mimics canonical WNT activation marked
by nuclear translocation of β-catenin and transcriptional
activation of downstream targets [29-31]. Since lithium
can be safely administered to patients and crosses the
brain–blood barrier [32], it might constitute a thera-
peutic means to induce radiosensitivity and improve sur-
vival in SHH/mutant TP53 patients.
To test our hypothesis we first assessed the impact of
TP53 mutations on survival of children with medullo-
blastoma treated with craniospinal irradiation. We then
examined the role of lithium-mediated WNT activation
in abrogating the radioresistance observed in TP53 mu-
tant medulloblastoma cells. Our results suggest that lith-
ium administration with radiation therapy may be a safe
and efficacious therapy for childhood medulloblastoma.
Materials and Methods
Patient and sample description: We collected clinical and
biological data on 314 patients from the Hospital for
Sick Children (Toronto, Canada), Division of Molecu-
lar Genetics and Department of Paediatric Oncology,
Haematology and Immunology, University Hospital
(DKFZ) (Heidelberg, Germany), Northern Institute for
Cancer Research, Newcastle University (Newcastle, United
Kingdom) [33], Institute of Neuropathology, University
of Bonn Medical Centre (Bonn, Germany) [34] and the
Medulloblastoma Advanced Genomics International
Consortium (MAGIC) [35] cohorts. Patients between 5
and 19 years of age were eligible for this study. We ex-
cluded patients younger the 5 years of age at diagnosis
under the assumption that they were not eligible for ra-
diation therapy according to the most of the current
medulloblastoma protocols. All patient samples were
procured in accordance with the Research Ethics Board
of their corresponding institution. For 300 (95.5%) pa-
tients complete clinical and survival data were available
for analysis. Samples from all centers were either ob-
tained as frozen tissue or formalin fixed paraffin em-
bedded (FFPE) biopsies and processed to determine
subgroup β-catenin and TP53 status as previously de-
scribed [10].
Cell line work: Human medulloblastoma wild-type
TP53 cells lines: ONS76, D283MED, MEB-MED-8A and
TP53 mutant cell lines: UW228 and Daoy were cultured
Zhukova et al. Acta Neuropathologica Communications  (2014) 2:174 Page 3 of 12as previously described [36,37]. Normal neural stem cells
(NNSC) Hf5205 were cultured as previously described
[38]. ONS76, D283MED, MEB-MED-8A, UW228 and
Daoy cells were provided by Taylor Lab (The Hospital
for Sick Children, Toronto) and Brain Tumor Research
Centre (BTRC) repository (The Hospital for Sick Chil-
dren, Toronto). NNSC, Hf5205, were provided by Dirks
Lab (The Hospital for Sick Children, Toronto). All cells
were authenticated including verification of TP53 status.
Lithium chloride (Sigma, 02685-1EA), was used at a final
concentration of 2 mM in regular culture medium. Radi-
ation exposure was performed using a Nordion Gamma-
cell 40 irradiator with the central dose rate 1.24 Gy/min.
Single discrete doses of 1 to 8Gy were delivered accord-
ing to experimental design.
Clonogenic experiments: To generate radiation sensi-
tivity curves cells were seeded at specific numbers in
triplicates into 10 cm dishes to yield between 50 and 150
colonies. Cells were allowed to adhere overnight and
then irradiated with the range of single doses from 1 to
5Gy. The medium was changed after irradiation and
cells were maintained at 37°C for 14 days to allow col-
ony formation. The colonies (50 cells/colony threshold)
were then fixed and stained with Crystal violet (0.1%)
and counted manually. The surviving fractions were cal-
culated after adjustment for plating efficiency of non-
irradiated controls as follows [39]:
SF survival fractionð Þ ¼ ½ number of colonies observedð Þ
 number of cells platedð Þ
 PE plating efficiency of controlð Þ
PE plating efficiency of controlð Þ
¼ number of colonies observed in non‐irradiated sampleð Þ
 number of cells platedð Þ
Survival fraction at 2 Gray (SF2) calculations: To fit
the clinical relevance, the radiation dose of 2Gy was se-
lected to match the daily fraction size commonly used in
paediatric clinical practice [40]. The SF2 was calculated
as following:
SF2 ¼ ½ number of colonies observed after treatment with 2Gyð Þ
 number of cells platedð Þ
 PE plating efficiency of controlð Þ
Sensitizer enhancement ratio (SER) calculations: SER
was calculated as the radiation dose needed for radiation
alone divided by the radiation dose together with of lith-
ium needed to eliminate 90% of cells [36].
Same corresponding cell lines simultaneously main-
tained without lithium chloride were used as controls.
Data from three independent experiments performed in
triplicate were each plotted as a function of radiation
dose on a semi-logarithmic scale.Transfection experiments: For each cell line, 3 × 105
cells were transiently transfected in parallel with 2 μg of
the plasmid-of-interest DNA or 2 μg pcDNA3 control
plasmid (either GFP- or FLAG-tagged) by nucleoporation,
as per the manufacturer’s instructions, using the Amaxa
Mouse Neural Stem Cell Kit (Nucleofector, Lonza, VPG-
1004) and X001 program. At 24 hours post transfection
the transfection efficiency of 59.9% ± 12.3% for the
pcDNA3-TP53R175H/pcDNA3-GFP plasmid combin-
ation and 90% for the pcDNA3-S33Y/pcDNA3-FLAG
plasmid combination was estimated by manual count-
ing of GFP- and FLAG- positive cells under immuno-
fluorescent microscopy. Subsequently, cells were irradiated
between 24 and 48 hours and plated for clonogenic assay
as described above. Plasmids used: pcDNA3-TP53R175H,
pcDNA3 (courtesy of Dr. David Malkin, The Hospital for
Sick Children, Toronto), and pcDNA3-S33Y β-catenin
[41] obtained from Addgene: http://www.addgene.org/.
Clonogenic experiments with combination of lithium
and radiation exposure: ONS76 and UW228 cells were
cultured, as described above. Cells were exposed to 2 mM
lithium chloride for 24 hours, and then irradiated with the
range of doses from 2 to 8Gy. Drug-containing medium
was replaced with normal growth medium. Clonogenic
experiments were performed as described above.
Immunofluorescence – β-catenin nuclear translocation:
Cells transfected with S33Y-CTNNB1 mutation and/or
pre-treated with 2 mM of lithium chloride for 24 hours
were cultured as described above. β-catenin expression
was visualized by immunofluorescence using a Quorum
Spinning Disk Confocal Microscope. The antibodies used
were: a mouse anti-β-catenin (BD Transduction Labs,
6101153) and a donkey-anti-mouse IgG conjugated with
Alexa Fluor 488 (Invitrogen, A21202); both were used at
1:500 dilution. All experiments were repeated three times.
β-catenin luciferase reporter assay: For the reporter
assay, 1 × 105 cells were plated in 24-well plates in tripli-
cate per sample and left to attach overnight. Cells were
transiently transfected in parallel with either 0.5 μg of
the TCF reporter construct (M50 Super 8xTOPFlash)
DNA or 0.5 μg of the mutated reporter construct (M51
Super 8×FOPFlash) DNA [39,42] together with 1 ng of
Renilla DNA. Plasmids were obtained from Addgene:
http://www.addgene.org/. Transfections were performed
using Lipofectamine 2000 (Invitrogen, 11668–027) ac-
cording to manufacturer’s protocol. After 4 hr post
transfection medium was replaced with the regular
growth medium and cells were treated with 2 mM of
lithium chloride for 24 hr. TCF-mediated transcrip-
tional activity was determined by the ratio of TOP-
Flash/FOPFlash luciferase activity, normalized to the
Renilla luciferase activity, using Promega Dual Luciferase
Reporter Assay System, (Promega, E1960). 3 independent
experiments were done.
Table 1 Patient characteristics according to TP53 status
Variable TP53 wild-type TP53 mutant p-value
N 261/314 (83.1%) 53/314 (16.9%)
Age (median, range) 9.0 (5.0 – 18.5) 10.0 (5.0 – 17.0) p = 0.4
Gender (male) 154/261 (59%) 25/53 (47.2%) p = 0.1
Histology
LCA 31/261 (11.9%) 23/53 (43.4%) p = 0.0001*
Classic 204/261 (78.2%) 25/53 (47.1%)
Desmoplastic/nodular 21/261 (8.0%) 2/53 (3.8%)
Missing 5 /261 (1.9%) 3/53 (5.7%)
M+ disease 80/261 (30.7%) 7/53 (13.2%) p = 0.01
Subgroups
WNT 72/261 (27.6%) 15/53 (28.3%) p = 0.003**
SHH 59/261 (22.6%) 36/53 (67.9%)
Group 3 37/261 (14.2%) 0/53 (0%)
Group 4 92/261 (35.2%) 1/53 (1.9%)
Missing 1/261 (0.4%) 1/53 (1.9%)
Death 54/261 (20.7%) 24/53 (45.3%)
WNT 5/72 (6.9%) 0/15 (0%) p = 0.004***
SHH 9/59 (15.3%) 24/36 (66.7%)
*Incidence of LCA histological variant in TP53 wild-type and TP53 mutant patients;
**Incidence of TP53 mutations in WNT and SHH patients; ***Incidence of death in
TP53 mutant population in WNT and SHH patients.
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escent microscopy and imaging: Medulloblastoma and
NNSC cells were cultured on cover slips in 6-well
dishes and fixed as described above. Cells were pre-
treated with 2 mM lithium chloride for 24 hours and
then exposed to 5Gy single dose of radiation. Untreated
and non-irradiated cells were used as control. Speci-
mens were collected at 30 min, 4 and 24 hours post ra-
diation. At appropriate time points, cells were fixed and
processed as described above. The antibodies used
were: a mouse anti-phospho-histone-H2AX (Ser139)
(Millipore, 05–636), 1:800 dilution, and an Alexa Fluor
488 donkey-anti-mouse IgG (Invitrogen, A21202), 1:500
dilution. For quantification of γH2AX foci 3 independent
experiments were performed. Between 100 and 250 nuclei
were examined and foci were counted using Perkin Elmer
Velocity 6.0.1 software (Perkin Elmer, USA) with 0.2um
cut off for foci size. The following procedure was applied
to decrease inter-experimental variability: 1) all 3 experi-
ments were pooled together and individual values were
used for analysis [43]; 2) average number of foci per nu-
cleus was calculated; 3) outliers, which were estimated as
nuclei containing > 2 standard deviation (2 SD) from the
average for the treatment subgroup, were eliminated; 4)
baseline number of foci per nucleus was estimated in the
untreated sample as average plus 2 SD; 5) to remove back-
ground noise nuclei with baseline or less number of foci
were eliminated from experimental samples and the
remaining nuclei were considered γH2AX-positive for fur-
ther calculations; 6) number of foci in γH2AX-positive nu-
clei was calculated and expressed as an average number of
foci per nuclei; 7) comparison was done between treat-
ments using average number of foci per nucleus and num-
ber of γH2AX-positive cells as defined above.
Normal neuronal stem cell viability experiments:
NNSC (Hf5205) were cultured and pre-treated with
lithium chloride as previously described. Cells were
counted five days after radiation using a Cell Viability
Analyzer (Vi-Cell XR, Beckman Coulter). Survival curves
were generated as described above. The figure was plotted
from three independent experiments performed in tripli-
cate each.
Statistical analysis: Overall survival was estimated
using the Kaplan-Meier method with significance (α =
0.05) based on long-rank test, using Stata 12 for OS X.
OS was defined as the interval between the date of diag-
nosis and the date of death of any cause or the date of
the last follow-up visit.
For biological data results were expressed as the mean ±
SE of three or more independent experiments carried
out in triplicate. Statistically significant differences be-
tween samples were determined using Student 2-tailed
t-test and two-way ANOVA with the Bonferroni correc-
tion method, when appropriate, using GraphPad Prismversion 5.00 for Windows, GraphPad Software, San
Diego California USA, www.graphpad.com; p value <
0.05 was considered significant. The error bars in the
figures represent SEs.
Results
Impact of TP53 mutations on children treated with ir-
radiation. In order to assess the role of TP53 mutations
in medulloblastoma patients who received radiotherapy,
we selected patients between 5 and 19 years old who re-
ceived craniospinal radiation according to local standard
of care protocols. The complete characteristic of the co-
hort is summarized in Table 1. We identified somatic
TP53 mutations in 16.9% (53/314) of cases. Median age
at diagnosis and gender distribution was not different
between wild-type or mutant TP53 patients. We ob-
served a higher proportion (p < 0.01) of metastatic dis-
ease in TP53 wild-type patients (Table 1). Anaplastic
histology was more prevalent in TP53 mutant patients
(p < 0.001).
As previously reported, no TP53 mutations were ob-
served in groups 3 and 4 tumors while 17.2% (15/87) of
WNT and in 37.9% (36/95) of SHH tumors harbored
mutations.
Five-year OS for children with TP53 wild-type and
mutant tumors was 80.6% ± 2.8% and 55.9% ± 7.4% re-
spectively (p < 0.0001) (Figure 1A). For children with
Figure 1 Survival estimates for medulloblastoma patients by TP53 status. In all figures TP53 status is demonstrated by solid line (wild-type)
and dotted line (mutant). A) OS survival for all medulloblastoma patients. B) OS for patients with SHH medulloblastoma. C) OS for patients with
WNT medulloblastoma.
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type patients was 86.8% ± 4.7% versus 36.6% ± 8.7% for
TP53 mutant ones (p < 0.0001) (Figure 1B). In contrast,
the 5-year OS in children with WNT medulloblastoma
was 95.7% ± 3% for the TP53 wild-type and 100% for
the TP53 mutant cases (p = 0.4887) (Figure 1C). The
difference in patient survival between TP53 mutant and
wild-type tumors outside the WNT subgroup was more
striking here than in our previous report, because the
latter included patients who did not receive radiother-
apy [10]. TP53 mutations clustered with 66.7% of
deaths of SHH patient in this age group. Furthermore,
of the TP53 mutant cancers that recurred, 42% (22/53)
were SHH and only 16% (1/6) were WNT (p < 0.0001).
Together, these findings suggest that in children with
SHH tumors receiving radiotherapy, TP53 mutation is a
marker of poor outcome. This effect is entirely drivenFigure 2 Survival of medulloblastoma cells harboring alterations in T
of TP53 wild-type: D283MED, ONS76, MEB-MED-8A(blue) and TP53 mutant:U
superior radiation resistance (p < 0.01). B) Transfection of the TP53 wild-typ
TP53 mutation (red) results in increased survival of the cells under the radiatio
with S33Y-CTNNB1 mutation (red) resulted in sensitization of cells to radi
(UW228) with mutant S33Y-β-catenin construct results in nuclear translocation
observed in the control cells, transfected with pcDNA3 construct (top pan
nucleus (yellow).by SHH tumors, as it was not observed in WNT acti-
vated tumors. This clinical observation suggests that
TP53 mutation confer poor survival in part due to radi-
ation resistance in non WNT tumors while this is re-
versed in WNT activated medulloblastomas.
TP53 mutations confer radiation resistance in medul-
loblastoma cell lines. In order to determine the re-
sponse to radiation in TP53 wild-type and mutant
medulloblastoma cells we used two approaches.
First, we performed a series of clonogenic assays post
radiation treatment using a panel of TP53 wild-type
and TP53 mutant non-isogenic medulloblastoma cell
lines. We observed significantly higher survival in re-
sponse to radiation treatment in TP53 mutant cell lines
(Daoy and UW228), compared to TP53 wild-type cell
lines (ONS76, MEB-MED-8A and D283MED) (p < 0.01)
(Figure 2A). Specifically, survival fraction at clinicallyP53 and CTNNB1 after radiotherapy. A) Clonogenic assay on a panel
W228, Daoy (red) medulloblastoma cell lines. TP53 mutant cells exhibit
e (blue) medulloblastoma cells (ONS76) with R175H dominant-negative
n treatment (p < 0.01). C) Transfection of TP53mut cells (UW228) (blue)
ation (p < 0.05). D) Transfection of TP53 mutant medulloblastoma cells
of β-catenin (bottom panel), no nuclear translocation of β-catenin is
el): β-catenin (green), nucleus (red), co-localization of β-catenin to
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67% ± 4.7% for Daoy, 64% ± 2.2% for ONS76, 54% ±
4.7% for D283MED and 33% ± 9.9% for MEB-MED 8A
cells (p < 0.001) (Additional file 1: Figure S1A).
Second, to further confirm the pro-survival effect of
TP53 mutation under radiation exposure in an isogenic
system, the wild-type TP53 cell line (ONS76) was transi-
ently transfected with an expression vector for the
dominant-negative TP53-R175H mutation. Expression of
the mutant p53 protein resulted in a significant increase
(p < 0.01) in radiation resistance in transfected cells
compared to the empty-vector control (Figure 2B). The
SF2 was 89% ± 2% in TP53-R175H transfected cells ver-
sus 57.4% ± 1.8% in the parental TP53 wild-type cells
(p < 0.001) (Additional file 1: Figure S1B).Figure 3 Survival of TP53 mutant medulloblastoma (UW228) cells afte
A) Survival curves for TP53 mutant cells given increasing radiation doses fo
(p < 0.01). B) Increase in luciferase activity in treated cells (red) over control
of the nuclear translocation of β-catenin (bottom panel); β-catenin (green), nu
lithium. D) γH2AX foci in non-irradiated cells and 24 hours post irradiation: γHActivation of WNT signaling via CTNNB1 mutation
(S33Y) sensitizes TP53 mutant medulloblastoma cells
to radiation. To test whether WNT pathway activation
results in radiosensitivity in medulloblastoma cells, we
examined the role of exon 3 mutations and subsequent
WNT pathway activation in sensitizing TP53 mutant
medulloblastoma cells to radiation. UW228, TP53 mu-
tant/CTNNB1 wild-type medulloblastoma cells were
transfected with vector containing the activating S33Y
mutation (TP53-T155N/CTNNB1-S33Y) and the empty
vector control (TP53-T155N/pcDNA3). Expression of
the S33Y-mutant β-catenin protein in TP53 mutant me-
dulloblastoma cells sensitizes these cells to radiation (p <
0.05) (Figure 2C). This was accompanied by marked nu-
clear translocation of β-catenin in the cells (Figure 2D),r the combination treatment with 2 mM lithium and radiation.
llowing 24 hours exposure to lithium (red) and untreated control (blue)
(blue) in TP53 mutant cells (p < 0.01). C) Immunofluorescent imaging
cleus (DAPI-red), co-localization (yellow) following 24 hours exposure to
2AX foci (green), nucleus (blue).
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tumors [22,26,28].
These findings suggest that TP53 mutations confer
radioresistance in medulloblastoma cells while WNT ac-
tivation results in radiosensitizsation.
Pharmacological activation of WNT by lithium reduces
radioresistance in medulloblastoma with mutant TP53.
Since lithium is known to activate WNT signaling via in-
hibition of GSK3β, we examined whether pharmacological
intervention could mimic the radiosensitivity observed in
the WNT group and sensitize TP53 mutant cells to radi-
ation. Pre-treatment with lithium, resulted in significantly
increased (p < 0.01) radiation sensitivity of the treated cells
compared to the untreated parental cells (Figure 3A) The
sensitizer enhancement ratio was 1.3 at a surviving frac-
tion of 0.10 and the SF2 was 43.5% ± 1.5% for treated cells
versus 56.6% ± 3% for treated untreated cells controls (p <Figure 4 Survival of normal neuronal stem cells (Hf5205) after the co
curves for normal neuronal stem cells given increasing radiation doses follow
(p = 0.054). B) Immunofluorescent imaging of normal neuronal stem cells; abs
control (top panel) and lithium treated (bottom panel) cells, nucleus (DAPI-red
γH2AX foci (green), nucleus (DAPI-blue).0.01) (Additional file 1: Figure S1C and 1D). Activation of
the WNT signaling pathway by lithium was demonstrated
by increased luciferase activity, nuclear translocation of β-
catenin in treated cells and increased number of γH2AX
foci post radiation (Figure 3B,C and D). Interestingly,
lithium exposure also enhances radiation sensitivity of
TP53 wild-type cells as demonstrated with ONS76 cells
(Additional file 1: Figure S2A, B and C). In both TP53mu-
tant and TP53 wild-type cells we observed a higher num-
ber of γH2AX foci in lithium pre-treated cells in response
to radiation treatment; at 24 hours post irradiation we
found 36.6% of γH2AX foci increase in TP53 mutant cells
and 10.4% increase in TP53 wild-type ones, suggestive of
pharmacologically induced DNA break/repair mechanism
impairment (Additional file 1: Figure S3).
Lithium does not sensitize normal neuronal stem cells
to radiation. Since lithium may have detrimental effectsmbination treatment with 2 mM lithium and radiation. A) Survival
ing 24 hours of exposure to lithium (red) and untreated control (blue)
ence of the nuclear translocation of β-catenin (green) is observed in both
). C) γH2AX foci in non-irradiated cells and 24 hours post irradiation:
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to radiation, we used Hf5205 NNSCs as a surrogate to test
a combination effect of lithium and radiation therapy on
normal brain cells. Pre-treatment of NNSCs with lithium
did not result in decreased survival. Pre-treated cells dem-
onstrated a slight, though not statistically significant (p =
0.15), survival advantage over their untreated counterparts
(Figure 4A). SF2 analysis for both treated and untreated
cells revealed a somewhat increased survival for lithium
pretreated cells (33% ± 8% vs. 27% ± 3%, respectively
(p = 0.05) (Additional file 1: Figure S1E). Lithium pre-
treatment did not result in nuclear translocation of β-
catenin (Figure 4B), nor in increased gamma γH2AX foci
formation: at 24 hours post irradiation we observed 3.1 ±
0.4 foci per nucleus in lithium treated NNSCs and 2.7 ±
0.3 foci per nucleus in untreated controls (Figure 4C and
Additional file 1: Figure S4).
Discussion
In this study, we confirmed that TP53 mutations remain a
poor prognostic marker and account for a high proportion
of the treatment failure in SHH subgroup medulloblas-
toma patients receiving radiation treatment, while TP53
mutant WNT patients demonstrate excellent outcomes.
The importance of this finding is further highlighted
through molecular studies in which we demonstrated that
TP53 mutant medulloblastoma cells are more resistant to
radiation. We further confirmed our results using an iso-
genic in vitro model, transfecting TP53 wild-type cells
with a known dominant-negative TP53 mutation. These
findings are in agreement with previously published data
suggesting a context-dependent role of TP53 in radiation
response [12,19-21,44].
Activation of WNT signaling either via increased levels
of β-catenin or pharmacologically with lithium radiosen-
sitized medulloblastoma cells, abrogated the pro-survival
effects of TP53 mutations [21,45]. This effect seems to
be highly tissue/tumor specific, as in the majority of
tumor types increased WNT signaling is associated with
tumor resistance to radiation. Recent studies suggested
that WNT/β-catenin activation contributes to radiation
resistance in the cancer stem cell population via the in-
duction of chromosomal instability, deregulation of mi-
totic spindles and increased tolerance to DNA damage
[46]. The WNT pathway has also been found to mediate
radiation resistance in both mammary progenitor cells
and human breast cancer cell lines [47,48], as well as in
esophageal and colorectal cancers [49,50]. Furthermore,
in glioblastoma multiforme mouse models and cell lines
transcriptionally active β-catenin is found in the stem-
like population of cells that display resistance to radi-
ation [51].
Pharmacological radiosensitizsation of medulloblastoma
cells by utilizing clinically tolerable doses of lithium priorand during radiation exposure adds a new and relatively
simple dimension to the current treatment of childhood
medulloblastoma. Since the decreased cell survival associ-
ated with the combination of lithium and radiation was
accompanied by nuclear translocation of β-catenin and
transcriptional activation of β-catenin TCF/LEF medi-
ated signaling it is reasonable to suggest that this bene-
ficial effect is due to WNT pathway activation in these
tumors. Since lithium sensitizes all medulloblastoma
cells to radiation, addition of lithium to current proto-
cols may be beneficial to all patients but specifically to
the lethal SHH TP53 mutant subgroup. In addition,
combination of lithium with small-molecule inhibitors
of the SHH pathway may represent an attractive regi-
men for high risk patients with SHH medulloblastoma.
Our results are especially exciting since, in our experi-
ments lithium does not activate WNT signaling in nor-
mal neuronal stem cells, nor does it sensitize them to
radiation. Moreover, we were able to observe marginal
improvement in NNSC survival treated with lithium,
which is in agreement with published reports demon-
strating protective capacity of lithium against radiation
in mouse models [52,53]. Taken together, our data sug-
gests that lithium is a tolerable and safe pharmacological
agent to be added to treatment of medulloblastoma.
Conclusion
In summary, we demonstrate here how combination of
genomic and genetic analysis of brain tumors can pre-
dict differential responses to current therapies, and pro-
vide insight into ways that favorable signaling pathways
may be mimicked by pharmacological intervention. We
recognize that despite being safely used in humans for
treatment of psychiatric disorders, lithium needs further
pre-clinical evaluation prior to administration to humans
for the purpose of medulloblastoma treatment. Never-
theless, our findings can also serve as proof of principle
for implementation of other drugs which abrogate the
detrimental effects of genetic events in the cancer thera-
peutic response.
Additional file
Additional file 1: Figure S1. Survival fractions at 2Gy (SF2) and SER for
medulloblastoma cells treated with radiation and combination of lithium
and radiation. A) SF2 for the panel of wild-type (blue) and mutant (red)
medulloblastoma cells exposed to radiation. B) SF2 for the TP53 wild-type
(blue) and R175H TP53 mutant (red) medulloblastoma cells. C) SF2 for
lithium treated TP53 mutant cells (red) comparing to untreated control
(blue). D) SER for lithium TP53 mutant cells (red) comparing to untreated
control (blue). E) SF2 for untreated NNSC (red) compared to treated with
lithium (blue); *p < 0.05, **p < 0.001. Figure S2. Survival of TP53 wild-type
medulloblastoma cells after the combination treatment with lithium and
radiation. A) Survival curves for TP53 wild-type cells given increasing
radiation doses following 24 hours exposure to lithium (red) and untreated
control (blue) (**p < 0.01). B) Increase in luciferase activity in treated cells
Zhukova et al. Acta Neuropathologica Communications  (2014) 2:174 Page 10 of 12(red) over control (blue) in TP53 wild-type cells (**p < 0.01). C) γH2AX foci in
non-irradiated cells and 24 hours post irradiation: γH2AX foci (green),
nucleus (DAPI-blue). Figure S3. DNA damage-repair response of TP53
wild-type (ONS76) and TP53 mutant (UW228) medulloblastoma cells to
combined treatment with 2 mM lithium and radiation. Both TP53 wild-type
A) and mutant cells B) demonstrate increased number of γH2AX foci (green)
in response to a combination treatment comparing to control (p < 0.0001);
nucleus (DAPI-blue). Figure S4. DNA damage-repair response of normal
neuronal stem cells to combined treatment with 2 mM lithium and
radiation. A and B) Normal neuronal stem cells demonstrate no increase
in the number of γH2AX foci (green) in response to a combination
treatment comparing to control (p < 0.0001); nucleus (DAPI-blue).
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